Egalet announces patent for its abuse-deterrence platform

Egalet ($EGLT) announced that its Guardian abuse-deterrence and drug delivery platform has been granted an additional patent by the U.S. Patent and Trademark Office. The patent is titled "Pharmaceutical Compositions Resistant to Abuse." It is the 14th U.S. patent covering the Guardian platform and its candidates. "This patent expands our intellectual property portfolio protecting products using our proprietary abuse-deterrent Guardian Technology," said Egalet CEO Bob Radie. "We will continue to strengthen our patent position covering our products which in some cases extends to 2033 to support our organic growth." According to the company website, "Guardian Technology utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew or dissolve and that turns to gel when exposed to water." Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.